Lung cancer is the second most form of cancers and remains the leading cause of cancer deaths. A variety of new treatments are helping to bring down the number of deaths from this deadly disease. Although non-small cell lung cancer remains accounts for most common type, but small cell lung cancer is also rising. A recent study has been conducted to look into the safety and effectiveness of medicine called tarlatamab in patients with small cell lung cancer. Tarlatamab is a new medicine that locates a protein called DLL3 on the cancer, allowing T cells to attack the cancer. T cells belong to body’s natural defense system called immune system. The participants received at least two other treatments for their SCLC.
In this study, they separate participants into two groups to receive tarlatamab 10mg or 100mg to determine which dose is most effective in reducing cancer with minimal side effects. The group with 10mg tarlatamab given, 40% of those responded to the testament and in group where 100mg tarlatamab was given, 32% were able to shrank cancer. Also, after taking tarlatamab at either dose, 59% of participants lived for at least six months without any growth in cancer.
As far as the side effects are concerned, the most common was CRS. The other common ones include decreased appetite, fever, anemia and constipation.
Thus, the study found that tarlatamab given every two weeks was able to shrank SCLC in participants who received previous treatments. Those given 10 mg tarlatamab dose had fewer side effects in comparison to those with 100mg tarlatamab dosage.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or Twitter today to stay informed and never miss an update!